BioAge Labs Director Rekha Hemrajani Receives 22,000 Stock Options

This Form 4 filing discloses that Rekha Hemrajani, a director of BioAge Labs, Inc. (ticker: BIOA), was granted 22,000 stock options on June 10, 2026. The options have an exercise price of $15.48 per share and expire on June 9, 2036. The entire option award will vest on the earlier of: (i) the date of the next annual meeting of the company's stockholders or (ii) the one-year anniversary of the grant date, subject to Hemrajani's continued service to the company on the applicable vesting date. The transaction was reported by attorney-in-fact Dov A. Goldstein on June 12, 2026. This represents a standard equity compensation award to a company director.